This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Genomic Health's CEO Discusses Q2 2012 Results - Earnings Call Transcript





Genomic Health, Inc. (GHDX)

Q2 2012 Earnings Call

August 8, 2012 4:30 pm ET

Executives



Emily Faucette – Senior Director, Corporate Communications and Investor Relations

Kimberly Popovits – Chairman of the Board, Chief Executive Officer and President

Bradley Cole – Chief Operating Officer

Dean Schorno – Chief Financial Officer

Steven Shak – Executive Vice President of Research and Development and Chief Medical Officer

Kathy Hibbs – Senior Vice President & General Counsel

Joffre Baker – Chief Scientific Officer

Randal Scott – Founder and Director, Genomic Health and Chief Executive Officer,

InVitae Corporation

Analysts



Dane Leone – Macquarie Research

Tycho Peterson – JPMorgan

David Clair – Piper Jaffray

Amanda Murphy – William Blair

Dan Leonard – Leerink Swann

Kevin DeGeeter – Ladenburg Thalmann & Co.

Scott Gleason – Stephens Inc.

Laura McGuigan – B. Riley

Nicholas Jansen – Raymond James

Presentation



Operator



Good afternoon. My name is Chuck, and I will be your conference operator today. At this time I would like to welcome everyone to Genomic Health’s Second Quarter 2012 Financial Results Conference Call. All participants are in a listen-only mode. Later we will conduct a question-and-answer session, and instructions will follow at that time. (Operator instructions)

I would now like to turn the call over to Emily Faucette, Senior Director of Corporate Communications and Investor Relations. You may begin your conference.

Emily Faucette

Thank you. Good afternoon everyone and welcome to Genomic Health conference call to review our second-quarter 2012 financial results. Before we begin, I would like to remind you that various remarks that we make on this call that are not historical, including those about our future financial and operating results, our plans and prospects, our ability to leverage our existing infrastructure, the success of our business strategy, economic benefits and value to payers of our tests, growth opportunities, future products, product enhancements and our product pipeline, demand for our tests and drivers of demand, payer coverage and progress in reimbursement and patient access, our investments in our business, clinical outcomes and timing of clinical studies, and product launches, and our expectations regarding our ability to comply with potential FDA regulation constitute forward-looking statements within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,029.80 -1.34 -0.01%
S&P 500 1,986.32 +2.19 0.11%
NASDAQ 4,520.4980 +1.5960 0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs